Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

Mon, 05th Feb 2024 14:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ECR Minerals PLC - Australia-focused gold exploration company - Drills seven successful holes, and says there is evidence of anomalous gold with the best result being 23.39 grammes per tonne of gold over metre. Says the best sample still has 4.7 g/t of gold in the tailings of the initial results. Chief Executive Officer Mike Whitlow says: "This is an encouraging start to our examination of Davey Road. Based on ECR's work historically in this region, our expectation was that any gold would be both course and confined within narrow veins. These preliminary results support this assumption and consequently analysis of the bulk samples is a necessary step before we have a full picture of the geology. There is plenty so far to be pleased with but these results are indicative only and we look forward to gaining a better understanding of the location once full testing is complete."

----------

FireAngel Safety Technology Group PLC - Coventry, England-based developer and supplier of home safety products - Expects to report sales for 2023 of approximately GBP41.0 million, down 29% from GBP57.5 million a year ago. Says UK Trade division performance suffered from the restructuring in its sales team. International sales also remained comparatively depressed in the second half of 2023, it says, as new legislation in Benelux in 2022, which had led to a surge in customer demand in the region for products during 2022, was not carried into 2023 as customers looked to reduce inventory intake.At December 31, FireAngel had net debt of GBP3.1 million, down from GBP4.8 million in 2022.

----------

Smarttech247 Group PLC - Cork, Ireland-based artificial intelligence-enhanced cybersecurity services provider - Expands its NoPhish email security tool to Google Mail users. Says NoPhish employs advanced analysis algorithms to evaluate the content and legitimacy of the reported emails, offering instant feedback to the user. In cases where an email is identified as suspicious or malicious, NoPhish takes proactive measures by automatically removing the email from the user's inbox, thereby mitigating the risk of accidental exposure to harmful content. CEO Raluca Saceanu says: "We are delighted to bring NoPhish to Google Mail users. Our mission has always been to provide cutting-edge, user-friendly cybersecurity tools and by making NoPhish available on one of the world's most widely used email platforms, we are taking a significant step towards making the digital world safer for everyone. The integration signifies major advancement in email security, as Google Mail's extensive user base can now benefit from Smarttech247's phishing detection and response technology. This expansion is part of our ongoing efforts to adapt and evolve in the face of ever-changing cyber threats, ensuring users across various platforms can enjoy a safer email experience."

----------

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious diseases - Says Sally Adams resigns as chief development officer, while Callum Scott is named as the new head of development, effective immediately. Says Adams will remain with the company part time for six months to ensure a "smooth and effective transition of responsibilities."

According to Scancell, Scott has more than 15 years of experience in vaccine research and development. Previously, he held the role of technical transfer & formulation development manager at biotech firm Allergy Therapeutics PLC. CEO Lindy Durrant says: "Firstly, on behalf of the Scancell board, I would like to express our sincere gratitude to Sally for her expertise and support over the last 15 years, both on the board and leading clinical development. She has been instrumental in establishing a highly motivated development team and has worked tirelessly to bring our highly differentiated and valuable cancer vaccines through to the clinic. We wish her all the best for the future. "I would also like to warmly welcome Callum to Scancell. His understanding of the challenges involved in developing, registering, and commercialising novel biologics will be of great value to Scancell as we continue to develop our lead assets SCIB1 and Modi-1 through later stage clinical development."

----------

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Appoints Camillo Pane as chair, effective February 19. He will be replacing Jo LeCouilliard. "Jo and the board feel that it is now appropriate for her to step down from the board and to appoint a new chair, with strong international consumer healthcare experience, to lead the company through its next strategic phase, focusing on organic growth through marketing and innovation," says Alliance Pharma. Senior Independent Director Richard Jones says: "On behalf of the Alliance board and the company I would like to thank Jo for her significant contribution to Alliance over the past five years and wish her well for the future. We look forward to Camillo joining the board as chair and harnessing his wide-ranging consumer healthcare experience to further enhance and develop our group strategy. In the meantime, the board remains focused on creating value for our shareholders by investing in growth whilst carefully managing our cost base."

----------

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
26 Apr 2011 08:33

Allergy gets FDA lift

Shareholders in allergy vaccine developer Allergy Therapeutics were making hay Tuesday after the US Food and Drug Administration (FDA) signalled the imminent lifting of the clinical hold on three of the company's products. The FDA said the clinical hold on the Investigational New Drug applications

Read more
28 Mar 2011 17:03

London close: Flat day for FTSE 100

A second attempt to spring into life evaporated ahead of the close on Monday and the top share index finished just a few points higher. Worries that Japanese carmakers may have to suspend production at their plants in China following the earthquake disruption have sent copper prices lower. As a res

Read more
28 Mar 2011 14:57

London afternoon: Shares mark time

Footsie finished the morning clinging on to positive territory and not much changed over the lunch time trading session, with a mildly firmer start on Wall Street providing little additional impetus. Worries that Japanese carmakers may have to suspend production at their plants in China following t

Read more
28 Mar 2011 14:06

Weak German market hits sales at Allergy Therapeutics

Pharmaceutical firm Allergy Therapeutics reported broadly flat revenues and profits for the six months ended 31 December, as a result of weakness in its core German market. First half revenue was £27.4m, slightly higher than £27.3m in 2009. Weakness in the euro also had a £1.1m impact on turnover.

Read more
20 Sep 2010 14:41

Small caps: Allergy Therapeutics, Goldplat, Avacta

Hay fever treatment specialist Allergy Therapeutics posted an operating profit for the year to June of £1.5m (2009: loss £5.1m) and cut losses to £116,000 from £11.4m. "On the regulatory front, the submission in March 2009 of Pollinex Quattro Grass, our ultra-short course four injection grass alle

Read more
22 Jul 2010 12:36

Allergy Therapeutics Sees FY Revenue GBP40.7M, Operating Profit

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN), a specialist pharmaceutical company focused on allergy vaccination, said Thursday, it expects to report revenue of GBP40.7 million, and an operating profit, for the year ended June 30, adding that the results was in-line with current market expe

Read more
1 Jul 2010 16:00

UK SMALLCAP ROUNDUP: Wills & Co Declared In Default

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps WILLS & CO STOCKBROKERS LTD, a small cap share dealer, has been declared to be in default by the Financial Services Compensation Scheme, four months afte

Read more
1 Jul 2010 12:57

UPDATE: Allergy Therapeutics Buys Swiss Co In Europe Push

(Adds analyst comment, detail.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Drug developer Allergy Therapeutics PLC (AGY.LN) Thursday said it agreed to buy its Swiss distributor, in one of its first steps in a new strategy to bolster its position in Europe. Allergy sa

Read more
1 Jul 2010 10:17

Allergy Therapeutics Buys Teomed For GBP700,000

LONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN) said Thursday it has agreed to acquire Teomed AG of Switzerland for a consideration of GBP700,000. MAIN FACTS: -The consideration for the acquisition of Teomed will comprise an initial cash payment of GBP500,000 on signing and a deferred

Read more
1 Jul 2010 10:04

Allergy Therapeutics Acquisition

TIDMAGY RNS Number : 6201O Allergy Therapeutics PLC 01 July 2010 ? Thursday 1 July 2010 Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") Allergy Therapeutics to acquire Teomed AG Expands Eur

Read more
24 Mar 2010 16:49

Cairn boss raises nearly £3m

Cairn Energy chief executive Sir Bill Gammell has raised nearly £3m from a share sale. Sir Bill sold 721,042 shares in the oil and gas producer and explorer at 414.4p each. He retains 3.21m shares, which is equivalent to 0.23% of the company's share capital. There have been two other sales by Si

Read more
1 Mar 2010 11:04

Small caps round-up: Beowulf, E2V, Mobile Doctors...

Beowulf, owner of several exploration projects in Sweden, continues to believe in the commercial prospects for its asset portfolio which has increased in both quantity and quality as well as resource type. Losses grew to £520,000 in 2009 from £399,000 the year before, but it says future price tren

Read more
22 Sep 2009 06:47

Tuesday tips round-up: Alliance Trust, MP Evans, Allergy Therapeutics

Alliance Trust's investment stance means that it is always in danger of trailing more heavily geared rivals when the stock market runs sharply ahead. However, on a rolling total return basis it continues to fare well ? ranked first out of its six largest peers over both one and two years. Further,

Read more
21 Sep 2009 08:04

Allergy Therapeutics narrows interim loss

Allergy vaccination group Allergy Therapeutics narrowed half year losses and said it is well placed to capitalise on the investments of the past. Pre-tax losses narrowed to £11.44m in the six month ended 30 June compared with a loss of £20.24m last time. Revenues increased by 22% to £37.8m, on a

Read more
9 Jul 2009 08:17

Small caps round-up: MBL, Netplay, Playtech...

Big profits and a maiden dividend have sent entertainment products distributor MBL charging higher Thursday. The supplier of CDs, DVDS and games reported a 42% hike in pre-tax profit for the year ended 31 March 2009 to £8.1m on revenue up 77.5% to £143.6m. Its major competitor, Entertainment UK, t

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.